Mogam Institute for Biomedical Research

The Green Cross Corporation

Eun Jung Song

Mijung Lee

Sujeong Kim

Soongyu Choi

Kyuhyun Lee

Hyung-Kwon Lim

Dong-Sik Kim

Young Seoub Park

Jongwha Won

Eun-Hee Lee

Kisu Kim

Ki Su Kim

Jae Chan Park

Jong Wha Won

Ok Jae Lim

Jae Hyun Park

Hye Ji Choi

Hyung Kwon Lim

Miyoung Oh

Yun Jung Lee

Ki Joon Cho

Shin A Jang

So Jung Lim

Ae Rin Yoon

Hyun Jung Cho

Sung Keun Kim

Jee Won Lee

Jun Hong Jeong

Jae-Chul Lee

Hae Naem Kwon

Su A Lee

Mun Kyung Kim

Gil-Jung Kim

Kwan Yub Kang

Eui Cheol Cho

A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.

Bispecific antibody specifically binding to GPNMB and CD3, and use thereof

An asymmetric fusion protein in which a fragment of an antibody binding to an insulin receptor, an iduronate-2-sulfatase (IDS) enzyme, and an Fc region are fused, and a use thereof are disclosed. The fusion protein can cross the blood-brain barrier (BBB) to deliver the IDS enzyme to the brain. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient can be used as a therapeutic agent for a central nervous system disease and particularly, is expected to prevent and treat various diseases caused by ribosome accumulation.

Fusion protein comprising IDS and use thereof

The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.

Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same

The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.

Anti-mesothelin antibody and composition comprising the same

The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.

Anti-glypican 3 antibody and pharmaceutical composition containing the same

Growing community of inventors

Yongin-si, South Korea

Eun Jung Song